文献速递贫血与红细胞疾病

端粒长度与体细胞突变同再生障碍性贫血免疫抑制治疗反应的相关性

Telomere length and somatic mutations in correlation with response to immunosuppressive treatment in aplastic anaemia.
PubMed 文献 · Br J Haematol · 2017-07-12

研究纳入393例再生障碍性贫血(AA)患者,评估核型异常、体细胞突变及骨髓单个核细胞端粒长度与免疫抑制治疗(IST)反应的关系。克隆性改变患者对IST反应较差但未达统计学显著;端粒长度>5·9的患者IST反应率更高(P=0·048)。结论认为克隆性改变或端粒磨损患者IST反应差,较短端粒可作为IST治疗反应的预测标志物。

要点

  • 18例(4·6%)患者出现疾病进展,单体7(50·0%)为疾病转化时最常见的细胞遗传学演变。
  • 32·9%的患者至少携带1个体细胞突变,最常见突变为NOTCH1、NF1、SCRIB、BCOR和DNMT3A。
  • 端粒长度>5·9的患者IST反应率更高(P=0·048)。

核心结论

  • 克隆性改变或端粒磨损的再生障碍性贫血患者对免疫抑制治疗反应较差。
  • 较短端粒不仅可作为生物标志物,还可作为免疫抑制治疗反应的预测标志物。

研究设计与样本

  • 研究纳入393例再生障碍性贫血患者。
  • 采用G显带/荧光原位杂交(FISH)检测克隆性(n=245),对88个造血相关基因进行靶向捕获测序(n=70)。
  • 通过FISH在单细胞水平检测骨髓单个核细胞端粒长度(n=135)。

主要发现

  • 18例(4·6%)患者出现疾病进展,单体7(50·0%)为疾病转化时最主要的细胞遗传学演变。
  • 32·9%的患者至少携带1个突变,最常见突变基因为NOTCH1、NF1、SCRIB、BCOR和DNMT3A。
  • 存在克隆性改变的患者(30·7%)较无克隆性改变组对免疫抑制治疗反应差,但该差异未达统计学显著。
  • 再生障碍性贫血患者端粒长度显著短于正常对照,存在克隆性改变的患者端粒长度显著更短。
  • 端粒长度>5·9的患者免疫抑制治疗反应率更高(P=0·048)。

关键数值与推荐

  • 端粒长度>5·9的患者免疫抑制治疗反应率更高(P=0·048)。
  • 存在克隆性改变的患者占30·7%,其免疫抑制治疗反应较无克隆性改变组差,但未达统计学显著。

临床怎么用

  • 原文结论认为较短端粒可作为免疫抑制治疗反应的预测标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated the frequencies of cytogenetic aberrations and somatic mutations of prognostic relevance in 393 patients with aplastic anaemia (AA). Clonality was determined by G-banding/fluorescence in situ hybridization (FISH) (n = 245), and targeted capture sequencing was performed for 88 haematopoiesis-related genes (n = 70). The telomere length (TL) of bone marrow nucleated cells was measured at the single cell level by FISH (n = 135). Eighteen (4·6%) patients showed disease progression, and monosomy 7 (50·0%) was the most predominant cytogenetic evolution at disease transformation. One third of patients (32·9%) presented at least 1 mutation; the most frequently mutated genes were NOTCH1, NF1, SCRIB, BCOR and DNMT3A. The patient group with clonal changes (30·7%) showed an adverse response to immunosuppressive treatment (IST), compared to the non-clonal group, but this finding did not show statistical significance. The TL of AA patients was significantly shorter than normal control and patients with clonal changes showed significantly shorter TLs. Patients with TL>5·9 showed a higher response rate to IST (P = 0·048). In conclusion, the patients with clonal changes or TL attrition showed a poor response to IST. Shorter TL can be used not only as a biomarker, but also as a predictive marker for treatment response to IST.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Park HS, Park SN, Im K, et al. Telomere length and somatic mutations in correlation with response to immunosuppressive treatment in aplastic anaemia. Br J Haematol. 2017. PMID: 28699658. doi:10.1111/bjh.14691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。